Otsuka Holdings Co., Ltd.
Japanese pharmaceutical holding company, parent of the Otsuka Pharmaceutical group; develops and manufactures pharmaceutical products, nutraceuticals, and nutritional supplements globally. Listed on the Tokyo Stock Exchange in December 2010 in what was then the largest pharmaceutical IPO.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2008
已完成
1
100.0%
暂无批准数据
- Otsuka Medical Devices and Otsuka Pharmaceutical launched the Paradise Ultrasound Renal Denervation system in Japan with National Health Insurance coverage effective March 1, 2026. - The system represents Japan's first ultrasound renal denervation treatment, targeting resistant hypertension patients whose blood pressure remains elevated despite three different antihypertensive medications including a diuretic. - The treatment works by reducing overactivity of sympathetic nerves surrounding renal arteries, offering a novel approach for patients at extremely high risk of serious cardiovascular complications. - Three major Japanese medical societies have collaborated to establish guidelines ensuring proper and safe treatment delivery based on facility requirements and patient eligibility criteria.
- Taiho Pharmaceutical exercised its option to develop and commercialize casdatifan, an investigational HIF-2α inhibitor, in Japan and certain Asian territories under a 2017 agreement with Arcus Biosciences. - Casdatifan is currently being evaluated in the global Phase 3 PEAK-1 trial for clear cell renal cell carcinoma, with Japan expected to participate starting in the first half of 2026. - This marks the fifth option exercise by Taiho from its collaboration with Arcus, expanding their partnership in oncology drug development across multiple therapeutic programs. - Clear cell renal cell carcinoma represents 75-80% of all kidney cancer cases, with kidney cancer showing rising worldwide incidence of approximately 400,000 new cases annually.
- Vera Therapeutics' atacicept demonstrated a statistically significant 46% reduction in proteinuria in patients with IgA nephropathy, exceeding the 35% reduction seen in Phase 2 trials. - The positive ORIGIN 3 Phase 3 results drove Vera's stock price up over 65% in pre-market trading, with the company planning FDA submission in Q4 2025. - Atacicept faces competition from Otsuka Holdings' sibeprenlimab, which has already filed for FDA approval and may reach market 6-9 months earlier than Vera's drug. - IgA nephropathy affects up to 50% of patients who may progress to end-stage kidney disease, representing a significant unmet medical need in nephrology.
- Taiho Pharmaceutical will acquire Araris Biotech for $400 million upfront with potential milestone payments of up to $740 million, valuing the deal at $1.14 billion. - Araris Biotech's proprietary AraLinQ™ platform enables the attachment of multiple cancer-fighting payloads to antibodies in a one-step process, creating more stable and effective antibody-drug conjugates. - The Swiss biotech company has three preclinical ADC candidates targeting hematological and solid tumors expected to enter clinical trials between 2025-2026, with operations continuing in Zurich after the acquisition.
- New comprehensive report provides critical insights into the global clinical trial landscape for Polycystic Kidney Disease, covering regional distribution, trial phases, and sponsor involvement across G7 and E7 countries. - Major pharmaceutical companies including Otsuka Holdings, Sanofi, and Pfizer are leading clinical development efforts, with the report highlighting prominent drugs currently in various trial phases. - The analysis offers valuable strategic intelligence for stakeholders by tracking enrollment trends, trial statuses, and success rates, enabling more informed investment and research decisions in PKD therapeutics.
